D.Rama Brahma Reddy

ABSTRACTAlzheimer's disease is one of the most devastating brain disorders of elderly humans. It is a decade has witnessed a steadily increasing effort directed at discovering the etiology of the disease and developing pharmacological treatment. Recent developments include improved clinical diagnostic guidelines and improved treatment of both cognitive disturbance and behavioral problems. Symptomatic treatment mainly focusing on cholinergic therapy has been clinically evaluated by randomized, double-blind, placebo-controlled, parallel-group studies measuring performance-based tests of cognitive function, activities of daily living, and behavior. The role of estrogen replacement, anti-inflammatory agents, and antioxidants is controversial and needs further study. Antidepressants, antipsychotics, mood stabilizers, anxiolytics, and hypnotics are used for the treatment of behavioral disturbance. Future directions in the research and treatment of patients with Alzheimer's disease include: applying functional brain imaging techniques in early diagnosis and evaluation of treatment efficacy; development of new classes of medications working on different neurotransmitter systems (cholinergic, glutamatergic, etc.) Keywords: Dementia, Symptoms and Stages of disease, Etiology, Pathology, Neurophysiology, Risk factors, Causes, Diagnosis, Treatment, Prevalence, 

The review on drug targeting in neoplastic disorders emphasizes the various targeting techniques for  effective treatment of the condition. Neoplasm refers to the new growth and its common in any individual, uncontrolled neoplasm results in condition called neoplastic disorder or tumor or cancer. Globally 14.1 million cancer cases were reported in 2012 and the number is expected to reach 24 million by 2035. This review outlines the advances in drug targeting to the neoplastic disorders  keeping in view on the highlights the novel drug delivery systems like liposomes and particulate system like nanoparticles  problems associated with conventional chemotherapy and radiation therapy. It usage in treatment of cancer and effective targeting ways to target the tumor cells without affecting the normal cells. 

ABSTRACTA simple, Precised, Accurate method was developed for the estimation of Abiraterone by RP-HPLC technique. Chromatographic conditions used are stationary phase  Azilent  C18 (150mm x 4.6 mm, 5m )Mobile phase 0.01%KH2PO4:Acetonitrile  in the ratio of 60:40 and flow rate was maintained at 1.0 ml/min, detection wave length was 235 nm, column temperature was set to 30oC and diluent was mobile phase Conditions were finalized as optimized method. System suitability parameters were studied by injecting the standard six times and results were well under the acceptance criteria. Linearity study was carried out between 25% to150 % levels, R2 value was found to be as 0.999. Precision was found to be 0.7 for repeatability and 0.2for intermediate precision. LOD and LOQ are 1.629µg/ml and 4.937µg/ml respectively. By using above method assay of marketed formulation was carried out 100.81% was present. Degradation studies of Abiraterone were done, in all conditions purity threshold was more than purity angle and within the acceptable range .Full length method was not performed ; if it is done this method can be used for routine analysis of AbirateroneKeywords: HPLC ,  Abiraterone , Method development , ICH Guidelines